Management of Elevated LDL Cholesterol

Current Lipid Profile Assessment

The American Academy of Pediatrics recommends total cholesterol levels between 100-199 mg/dL, with the patient's current level being 217 mg/dL, classified as high 1
The patient's triglycerides are 130 mg/dL, within the normal range of 0-149 mg/dL 1
The patient's HDL cholesterol is 58 mg/dL, within the normal range of >39 mg/dL 1
The patient's VLDL cholesterol is 23 mg/dL, within the normal range of 5-40 mg/dL 1
The patient's LDL cholesterol is 136 mg/dL, above the recommended range of 0-99 mg/dL, according to the American College of Cardiology 2, 3

The American College of Cardiology recommends high-intensity statin therapy, such as atorvastatin 40-80mg, to achieve greater LDL-C reduction in patients not meeting target LDL-C levels on moderate-intensity statin therapy 2, 3
High-intensity statins like atorvastatin 80mg can reduce LDL-C by ≥50% on average, compared to 30-49% reduction with moderate-intensity regimens, as stated by the American College of Cardiology 4
The European Society of Cardiology recommends a target LDL-C of <70 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD) 5
The American Heart Association recommends a target LDL-C of <100 mg/dL for primary prevention in high-risk patients 6
The European Society of Cardiology recommends an even lower target of <55 mg/dL for very high-risk patients 5
A reduction of at least 50% from baseline LDL-C is recommended alongside these absolute targets, according to the European Society of Cardiology 5

The American Academy of Pediatrics and the American College of Cardiology recommend measuring lipid profile, ALT, and AST after 4-8 weeks of dose adjustment to assess response and safety 1, 2
The American Academy of Pediatrics recommends monitoring for potential myopathy symptoms (muscle cramps, weakness, asthenia) 1
The European Society of Cardiology recommends considering adding ezetimibe if target LDL-C levels are not achieved with maximum tolerated atorvastatin dose 5

The European Society of Cardiology recommends adding ezetimibe as second-line therapy, providing an additional 20-25% LDL-C reduction, if maximum tolerated atorvastatin dose fails to achieve target LDL-C 5
The European Society of Cardiology recommends considering PCSK9 inhibitors for patients who don't achieve goals on maximum statin plus ezetimibe 5
The European Society of Cardiology recommends considering bempedoic acid as an adjunct therapy if maximum tolerated atorvastatin dose fails to achieve target LDL-C 5